Integral Health Asset Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Integral Health Asset Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-500,000	Closed	-$1.28M	–	103
2024 Q2	$1.28M	Buy	+500,000	New	+$1.71M	0.12%	72
2024 Q1	–	Sell	-450,000	Closed	-$3.96M	–	99
2023 Q4	$3.96M	Buy	450,000 +350,000	+350%	+$2.87M	0.54%	61
2023 Q3	$1.15M	Sell	100,000 -150,000	-60%	-$2.88M	0.16%	65
2023 Q2	$6.33M	Hold	250,000	–	–	0.78%	48
2023 Q1	$8.05M	Buy	250,000 +10,000	+4%	+$312K	1.62%	28
2022 Q4	$4.43M	Buy	240,000 +90,000	+60%	+$2.06M	0.93%	40
2022 Q3	$4.05M	Buy	+150,000	New	+$3.04M	0.79%	46
2021 Q4	–	Sell	-50,000	Closed	-$1.39M	–	86
2021 Q3	$1.39M	Buy	+50,000	New	+$1.43M	0.4%	61

Other funds holding RVNC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

Integral Health Asset Management's RVNC Position: Q3 2024 in Review

Integral Health Asset Management sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2024, closing a stake of 500,000 shares — an estimated $1.28M sold.

Integral Health Asset Management first reported a position in RVNC in Q3 2021 and held it in 8 quarters. The position peaked at $8.05M in Q1 2023. 201 funds tracked by Wall St. Rank hold RVNC as of Q3 2024.

Integral Health Asset Management reported no remaining Revance Therapeutics, Inc. position as of Q3 2024 after selling out during the quarter.
Integral Health Asset Management sold 500,000 Revance Therapeutics, Inc. shares in Q3 2024, an estimated $1.28M.
Integral Health Asset Management first reported a position in Revance Therapeutics, Inc. in Q3 2021 and held it in 8 quarters.
Integral Health Asset Management's Revance Therapeutics, Inc. position peaked at $8.05M in Q1 2023.
201 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2024.

Based on Integral Health Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.